Sunday, June 2, 2019, Chicago, Illinois, 6:45 AM – 7:45 AM

Breakfast with the Investigators: Exploring the Role of PARP Inhibition in the Management of Ovarian Cancer

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:15 AM - 6:45 AM — Registration and Breakfast Buffet
6:45 AM - 7:45 AM — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Professor Jonathan A Ledermann
Professor of Medical Oncology
Clinical Director
University College London Cancer Institute
Director, Cancer Research UK and UCL Cancer Trials Centre
London, United Kingdom

Joyce F Liu, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Director of Clinical Research, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

David M O’Malley, MD
Medical Director, Gynecologic Oncology
Director, Clinical Research, Gynecologic Oncology
Co-Director, Gynecologic Oncology Phase I Program
ORIEN Physician Liaison for OSUCCC – James
The Ohio State University and The James Cancer Center
Columbus, Ohio

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro.
6:15 AM - 6:45 AM — Registration and Breakfast Buffet
6:45 AM - 7:45 AM — Educational Meeting

Meeting Agenda and Format

This unique activity will feature 3 distinct content modules during which the faculty will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

MODULE 1: Genetic Drivers of Ovarian Cancer Development and Current Testing Algorithms; PARP Inhibitors in the Management of Newly Diagnosed Disease

  • Frequency and clinical significance of germline and somatic BRCA mutations and other genomic signatures (eg, homologous recombination deficiency) that may predict benefit from PARP inhibition; similarities and differences among available genetic testing platforms
  • Design of, entry criteria for and efficacy and safety results from the Phase III SOLO-1 trial evaluating maintenance olaparib after first-line platinum-based chemotherapy for patients with advanced ovarian cancer and a BRCA mutation
  • FDA approval of maintenance olaparib after first-line platinum-based chemotherapy for patients with germline or somatic BRCA mutations and implications for clinical practice
  • Other ongoing Phase III clinical trials evaluating PARP inhibition alone or in combination with other systemic approaches in the first-line setting (eg, PRIMA, PAOLA-1, ATHENA, GOG-3005, DUO-O)

MODULE 2: Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer; Prevention, Recognition and Management of PARP Inhibitor-Associated Side Effects

  • FDA indications and patient selection for niraparib, olaparib or rucaparib for platinum-sensitive recurrence; patient- and disease-specific factors that influence the prioritization of one agent versus another
  • Recently presented results and clinical implications of the Phase II QUADRA study of niraparib for patients with relapsed ovarian cancer, regardless of mutation status, who have received 3 or more prior chemotherapy regimens
  • Emerging results from the Phase III SOLO-3 trial comparing olaparib monotherapy to chemotherapy for platinum-sensitive relapsed ovarian cancer with a germline BRCA mutation
  • Available data documenting the correlation between low baseline body weight or platelet counts and adverse events with niraparib; implications for initial dosing
  • Incidence and timing of gastrointestinal, hematologic and other toxicities observed in patients receiving PARP inhibitors; recommended monitoring protocols and indications for the use of supportive care measures and/or treatment modifications/delays

MODULE 3: Investigational Applications of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development

  • Mechanistic similarities and differences among approved and investigational PARP inhibitors; early clinical research experience with talazoparib and veliparib
  • Mechanisms of PARP inhibitor resistance, including BRCA reversion mutations; implications for future research and clinical practice
  • Early efficacy and safety data with the use of a PARP inhibitor combined with an anti-angiogenic agent; ongoing Phase III trials evaluating this approach for recurrent disease
  • Biologic rationale for and published research data (eg, from the TOPACIO and MEDIOLA trials) with the use of PARP inhibitors combined with anti-PD-1/PD-L1 antibodies; ongoing studies of these combinations

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer (OC).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in OC, and use the results of these assessments to guide long-term treatment planning, including clinical trial accrual.
  • Recognize the recent FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC and a deleterious or suspected deleterious BRCA germline or somatic mutation, and consider how the availability of this strategy affects current therapeutic algorithms.
  • Appreciate available clinical trial data with and approved indications for the use of FDA-endorsed PARP inhibitors for patients with platinum-sensitive and multiregimen-refractory OC in order to appropriately integrate these agents into routine clinical practice.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.
  • Develop an understanding of the mechanisms of action of, available data with and potential clinical roles for other investigational PARP inhibitors in preparation for their possible introduction into future clinical practice.
  • Recall the biologic rationale for and ongoing research efforts evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy or immunotherapy, and refer appropriate patients for clinical trial participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.


Thank you for your interest in our educational program. At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:15 AM on Sunday, June 2nd. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients, and meal service will be offered based on availability. If you have any questions, please feel free to contact us via email at or call (800) 233-6153.